Multiple Sclerosis Agents

Random Miscellaneous Quiz

Can you name the Multiple Sclerosis Agents?

Quiz not verified by Sporcle

 plays        
How to Play
HintAnswer
SE: HR reduction of 10-20 bpm, occasionally bradyarrhythmias or AV block -- screen for cardiac dz (6 hr monitoring w/ first dose). Macular edema in 1% (reversible). Check varicella
MOA: Immune modulator, exact mechanism not known.
Alemtizumab class
SE: Localized inj site reactions. Self-limited (15-20 min) acute rxn resembling a panic attack (palpitations, dyspnea, flushing) -- not an indication to stop tx
Tizanidine class
MOA: Immunomodulator/antineoplastic
SE: Inj site rxn w/ high doses, flu-like s/s (responds well to naproxen), monitor liver fx, may develop neutralizing Ab, may increase depression.
Baclofen class
SE: Seizures at higher than recommended doses (contraindicated in pts with a hx of seizure)
Use: Depression. Also helps with pain
Dose: SC injection every other day
Venlafaxine class
Dose: SC injection 2-3 times weekly
MOA: Synthetic form of myelin basic PRO copolymer 1. Binds to MHC molecules. Competes w/ myelin antigens for presentation to T cells.
Bupropion class
Methylprednisone class
Rituximab class
Duloxetine class
Second line agent given IV monthy
Dalfampridine class
Axathioprine class
Plasmapheresis class
MOA: Potassium channel blocker. Possibly increases conduction in demyelinated axons
HintAnswer
IFN beta 1-a (Rebif) class
MOA: Antimetabolite and antifolate
Gabapentin class
Second line agent for RRMS that produces reduction in progression of disabilty
Methotrexate class
MOA: Anti-organ rejection drug
Dose: 1 gram/day IV for 3-5 days
Use: Fatigue
First line RRMS agent injected SC daily
Mitoxantrone class
Dose: 1250 mg/day PO for 3-5 days
Use: Depression. Also helps with fatigue
SE: Risk of progressive multifocal leukoencephalopathy. Rare fatal viral (polymyxoma JC virus) reactivation infxn affecting white matter in immunosuppressed (only a risk to pts w/
Dose: Oral. In extreme cases intrathecal
MOA: Purine analog
Use: pain and paroxysmal disorders
First line drugs for disease modification
IFN beta 1-b (Betaseron) class
SE: Thyroid disorders, ITP (with fatal brain hemorrhage), infections.
Second line agent: RRMS. Reduced relapses & progression of disability
Methylphenidate class
Use: For pts who do not respond to corticosteroids during acute attacks
MOA: Monoclonal Ab. Shows functional improvement not just slowing of decline
HintAnswer
Dose: Oral daily (first PO MS drug)
Off line agent used in the treatment of acute attacks
Use: Fatigue, cognitive impairment (long acting agent)
Excreted by kidney: contraindicated in moderate to severe renal failure
Dose: IM weekly
Prednisone class
Daclizumab class
MOA: Sphingosine 1-phosphate receptor modulator. Sequesters lymphocytes.
Second line agent: RRMS, SPMS, Progressive Relapsing MS
Cyclophosphamide class
Natalizumab class
Use: treatment of spasticity
Dose: IV infusion every 3 months
Modafinil class
IFN beta 1-a (Avonex) class
Fingolimod class
Carbamazepine class
Tricyclic class
MOA: alkylating agent
Glatiramer acetate class
Mycophenolate class
Second line agent MOA: monoclonal Ab

Friend Scores


  Player Best Score Plays Last Played
You You haven't played this game yet.

You Might Also Like...

Extras

Created Oct 18, 2011ReportNominate
Tags:agent, multiple